Ambroxol

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.